3-MONTH SUSTAINED-RELEASE FORM OF TRIPTORELIN IN PATIENTS WITH ADVANCED PROSTATIC ADENOCARCINOMA - RESULTS OF AN OPEN PHARMACODYNAMIC AND PHARMACOKINETIC MULTICENTER STUDY

The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapept yl) to be administered every 3 months were evaluated in 14 patients wi th advanced prostate carcinoma. After one single injection, the mean t ime to reach the surgical castration testosterone range is 22 days, an d this effective testosterone suppression is maintained for the 3-mont h therapy. After a first plasma surge (35.70 ng/ml) occurring 2.5 h af ter injection and a rise between day 17 and day 31 (maximum on day 24: 0.32 ng/ml), the mean triptorelin plasma level is stable(0.06 +/- 0.0 5 ng/ml) and maintained until day 91. This new formulation was well to lerated both locally and systemically.